MPI INDIUM DTPA IN 111 (indium in-111 pentetate disodium) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 1982.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MPI Indium DTPA In 111 is a radioactive diagnostic agent approved in 1982 for intrathecal administration to visualize cerebrospinal fluid flow and detect abnormalities in the central nervous system. The radiopharmaceutical uses indium-111 pentetate disodium as its active component, which localizes to the CNS via direct intrathecal injection. It functions as a diagnostic imaging tool to assess neurological conditions and CSF dynamics.
This mature, diagnostics-focused product operates in a stable but contracting market with minimal team growth expected as the product approaches loss of exclusivity.
Radiopharmaceutical Activity
Radioactive Diagnostic Agent
Working on MPI Indium DTPA In 111 places you in a niche diagnostic radiopharmaceutical portfolio with limited growth trajectory, primarily supporting hospital imaging departments and nuclear medicine specialists. Career advancement typically requires cross-functional movement into broader GE HealthCare imaging platforms or transition to higher-growth modalities such as PET agents or hybrid imaging systems.
Worked on MPI INDIUM DTPA IN 111 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.